

Referencing the NCCN Guidelines in Corporate Press Releases:

NCCN neither reviews nor approves external press releases announcing the inclusion of tests, agents, and/or therapies listed within the NCCN Guidelines. It is the responsibility of the company issuing the release to exercise due diligence and ensure accuracy in both content and attribution.

Please reference NCCN as follows:

Mention of "NCCN":

1st Occurrence: National Comprehensive Cancer Network® (NCCN®)

All Others: NCCN

Mention of "NCCN Guidelines":

1st Occurrence: NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®)

2nd Occurrence: NCCN Guidelines®

All Others: NCCN Guidelines

Mention of NCCN Category:

1st Occurrence: NCCN Category X

All Others: Category X

Please also adhere to the following guidance:

- Please provide the proper attribution and be clear in the press release headline that "[COMPANY]
 Announces Update to NCCN Guidelines to Include [PRODUCT]" (vs. "NCCN Announces Update
 to...").
- 2. NCCN Guidelines always recommend the generic drug name and not the brand name. If your press release contains information on a drug/therapy within the NCCN Guidelines, please be clear that NCCN is recommending the generic drug name. For example, "Generic name (Brand name) is a recommended option within NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines*)."
- 3. Include the following statement on all materials containing NCCN Content: "NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way."
- 4. Stay true to how the NCCN recommendation is written and avoid any subjective commentary.
- For any additional commercial use of NCCN Content in promotional and educational materials, NCCN requires a license and review of content (visit our <u>Permissions Webpage</u> or email <u>PermissionRequest@nccn.org</u>).